Clinical Trials Browser

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Phase 2 Not yet recruiting

41 enrolled

CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT04481035 2025-07-31

NF1NAC

Phase 2 Completed

5 enrolled 10 charts

CNS

Neurofibromatosis 1

NCT05735717 2025-07-24

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

70 enrolled

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Clinical Trials

NF114

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

NF1NAC

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Interventions for Reading Disabilities in NF1

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NF108-BINI

LS-NF1PNs

DoDNAC

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

plexifpc

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

DCLNF1

SynCoRAS

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Medical Treatment of "High-Risk" Neurofibromas

VitDBoneNF1

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

MEK Inhibitor

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

STARS

Protocol 102

Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

NFitor